Ken-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed for the management of gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea and vomiting. Pantoprazole, a proton pump inhibitor, acts by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, effectively suppressing gastric acid secretion. The synergistic action of these two agents provides symptomatic relief in conditions like gastroesophageal reflux disease (GERD), dyspepsia, and peptic ulcer disease, improving patient comfort and promoting mucosal healing. Ken-DSR Capsule is typically administered orally, with dosing tailored according to the severity of symptoms and clinical response. It is contraindicated in patients with known hypersensitivity to its components and should be used cautiously in individuals with liver impairment. Common adverse effects may include headache, dry mouth, or gastrointestinal disturbances. Prior consultation with a healthcare professional is essential to ensure appropriate use and to monitor for potential drug interactions or contraindications.